BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 36754936)

  • 1. Contrast-enhanced mammography in the assessment of residual disease after neoadjuvant treatment.
    Hogan MP; Horvat JV; Ross DS; Sevilimedu V; Jochelson MS; Kirstein LJ; Goldfarb SB; Comstock CE; Sung JS
    Breast Cancer Res Treat; 2023 Apr; 198(2):349-359. PubMed ID: 36754936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contrast-Enhanced Mammography Versus MRI in the Evaluation of Neoadjuvant Therapy Response in Patients With Breast Cancer: A Prospective Study.
    Bernardi D; Vatteroni G; Acquaviva A; Valentini M; Sabatino V; Bolengo I; Pellegrini M; Fantò C; Trimboli RM
    AJR Am J Roentgenol; 2022 Dec; 219(6):884-894. PubMed ID: 35731101
    [No Abstract]   [Full Text] [Related]  

  • 3. Contrast-Enhanced Mammography (CEM) for Detecting Residual Disease after Neoadjuvant Chemotherapy: A Comparison with Breast Magnetic Resonance Imaging (MRI).
    Barra FR; Sobrinho AB; Barra RR; Magalhães MT; Aguiar LR; de Albuquerque GFL; Costa RP; Farage L; Pratesi R
    Biomed Res Int; 2018; 2018():8531916. PubMed ID: 30533440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of contrast-enhanced mammography in the preoperative detection of ductal carcinoma in situ of the breasts: a comparison with low-energy image and magnetic resonance imaging.
    Wang L; Wang P; Shao H; Li J; Yang Q
    Eur Radiol; 2024 May; 34(5):3342-3351. PubMed ID: 37853174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imaging findings for response evaluation of ductal carcinoma in situ in breast cancer patients treated with neoadjuvant systemic therapy: a systematic review and meta-analysis.
    Ploumen RAW; de Mooij CM; Gommers S; Keymeulen KBMI; Smidt ML; van Nijnatten TJA
    Eur Radiol; 2023 Aug; 33(8):5423-5435. PubMed ID: 37020070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic Performance of MRI, Molecular Breast Imaging, and Contrast-enhanced Mammography in Women with Newly Diagnosed Breast Cancer.
    Sumkin JH; Berg WA; Carter GJ; Bandos AI; Chough DM; Ganott MA; Hakim CM; Kelly AE; Zuley ML; Houshmand G; Anello MI; Gur D
    Radiology; 2019 Dec; 293(3):531-540. PubMed ID: 31660801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamic contrast-enhanced mammography and breast MRI in the diagnosis of breast cancer and detection of tumor size.
    Tekinhatun M; Sabir N; Erdem E; Yilmaz S; Ufuk F
    Turk J Med Sci; 2024; 54(1):249-261. PubMed ID: 38812642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accuracy of Posttreatment Imaging for Evaluation of Residual in Breast Disease After Neoadjuvant Endocrine Therapy.
    Zhang C; Kosiorek HE; Patel BK; Pockaj BA; Ahmad SB; Cronin PA
    Ann Surg Oncol; 2022 Oct; 29(10):6207-6212. PubMed ID: 35831526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient perspectives on repeated contrast-enhanced mammography and magnetic resonance during neoadjuvant chemotherapy of breast cancer.
    Pires-Gonçalves L; Henriques Abreu M; Ferrão A; Guimarães Dos Santos A; Aguiar AT; Gouvêa M; Henrique R
    Acta Radiol; 2023 May; 64(5):1816-1822. PubMed ID: 36575580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-Dose, Contrast-Enhanced Mammography Compared to Contrast-Enhanced Breast MRI: A Feasibility Study.
    Clauser P; Baltzer PAT; Kapetas P; Hoernig M; Weber M; Leone F; Bernathova M; Helbich TH
    J Magn Reson Imaging; 2020 Aug; 52(2):589-595. PubMed ID: 32061002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is contrast-enhanced mammography (CEM) an alternative to MRI in assessing the response to primary systemic therapy of breast cancer?
    Sunen I; Isabel Garcia Barrado A; Cruz Ciria S; Garcia Maroto J; Gros Bañeres B; Garcia Mur C
    Eur J Radiol; 2024 Jan; 170():111270. PubMed ID: 38141263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Usefulness of automated breast volume scanner (ABVS) for monitoring tumor response to neoadjuvant treatment in breast cancer patients: preliminary results.
    D'Angelo A; Rinaldi P; Belli P; D'Amico R; Carlino G; Grippo C; Giuliani M; Orlandi A; Infante A; Manfredi R
    Eur Rev Med Pharmacol Sci; 2019 Jan; 23(1):225-231. PubMed ID: 30657564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contrast-enhanced spectral mammography in neoadjuvant chemotherapy monitoring: a comparison with breast magnetic resonance imaging.
    Iotti V; Ravaioli S; Vacondio R; Coriani C; Caffarri S; Sghedoni R; Nitrosi A; Ragazzi M; Gasparini E; Masini C; Bisagni G; Falco G; Ferrari G; Braglia L; Del Prato A; Malavolti I; Ginocchi V; Pattacini P
    Breast Cancer Res; 2017 Sep; 19(1):106. PubMed ID: 28893303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accuracy and precision of contrast enhanced mammography versus MRI for predicting breast cancer size: how "good" are they really?
    Taylor DB; Burrows S; Dessauvagie BF; Saunders CM; Ives A
    Br J Radiol; 2023 Mar; 96(1144):20211172. PubMed ID: 36753450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing Accuracy of Mammography and Magnetic Resonance Imaging for Residual Calcified Lesions in Breast Cancer Patients Undergoing Neoadjuvant Systemic Therapy.
    Um E; Kang JW; Lee S; Kim HJ; Yoon TI; Sohn G; Chung IY; Kim J; Lee JW; Son BH; Ahn SH; Ko BS
    Clin Breast Cancer; 2018 Oct; 18(5):e1087-e1091. PubMed ID: 29703689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of MRI-Directed Contrast-Enhanced Mammography for Biopsy Planning for Suspicious MRI-Detected Breast Lesions.
    Nida BA; Rooney TB; Miller MM
    AJR Am J Roentgenol; 2023 Feb; 220(2):202-211. PubMed ID: 36000664
    [No Abstract]   [Full Text] [Related]  

  • 17. MRI, Clinical Examination, and Mammography for Preoperative Assessment of Residual Disease and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer: ACRIN 6657 Trial.
    Scheel JR; Kim E; Partridge SC; Lehman CD; Rosen MA; Bernreuter WK; Pisano ED; Marques HS; Morris EA; Weatherall PT; Polin SM; Newstead GM; Esserman LJ; Schnall MD; Hylton NM;
    AJR Am J Roentgenol; 2018 Jun; 210(6):1376-1385. PubMed ID: 29708782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Head-to-head comparison of contrast-enhanced mammography and contrast-enhanced MRI for assessing pathological complete response to neoadjuvant therapy in patients with breast cancer: a meta-analysis.
    Kaiyin M; Lingling T; Leilei T; Wenjia L; Bin J
    Breast Cancer Res Treat; 2023 Nov; 202(1):1-9. PubMed ID: 37615793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of automated breast volume scanning with conventional ultrasonography, mammography, and MRI to assess residual breast cancer after neoadjuvant therapy by molecular type.
    Peng Y; Yuan F; Xie F; Yang H; Wang S; Wang C; Yang Y; Du W; Liu M; Wang S
    Clin Radiol; 2023 May; 78(5):e393-e400. PubMed ID: 36822980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contrast-Enhanced Mammography (CEM) compared to Breast Magnetic Resonance (MRI) in the evaluation of breast lobular neoplasia.
    Nicosia L; Rotili A; Pesapane F; Bozzini AC; Battaglia O; Pellegrino G; Fusco N; Porta FM; Frassoni S; Bagnardi V; Corso G; Sangalli C; Cassano E
    Breast Cancer Res Treat; 2024 Jan; 203(1):135-143. PubMed ID: 37787819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.